CRISPR-U™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With CRISPR-U™, Ubigene has
successfully edited over 3000 genes on more than 200 types of cell lines.
Objective
To create a Human DR1 Knockout
model in cell line by CRISPR-U™-mediated genome engineering.
Target gene info
Official symbol
DR1
Gene id
1810
Organism
Homo sapiens
Gene type
protein-coding
Official full symbol
down-regulator of transcription 1
Also known as
NC2, NC2-BETA, NC2B, NCB2
Genomic regions
Chromosome 1
Summary
This gene encodes a TBP- (TATA box-binding protein) associated phosphoprotein that represses both basal and activated levels of transcription. The encoded protein is phosphorylated in vivo and this phosphorylation affects its interaction with TBP. This protein contains a histone fold motif at the amino terminus, a TBP-binding domain, and a glutamine- and alanine-rich region. The binding of DR1 repressor complexes to TBP-promoter complexes may establish a mechanism in which an altered DNA conformation, together with the formation of higher order complexes, inhibits the assembly of the preinitiation complex and controls the rate of RNA polymerase II transcription.
Strategy Summary
This gene has 0 protein coding transcripts：
Frame-shift
Fragment A
Fragment B
gRNA Detail
Strategy
Project Comprehensive Difficulty Assessment
According to the Red Cotton database: the DR1 gene is evaluated as high lethality riskin cell line, and the CRISPR gene-editing strategy design is Unknown. Knockout project comprehensive difficulty is thus assessed as Unknown. KO experiment is not recommended.
Red Cotton™ Notes
Gene
DR1
had been KO in hek293t cell line.
In all cell lines, there is
3.3% cells with low expression level,
96.7% cells with medium expression level
of DR1 gene.
Cell line is not selected, unable to assess the accurate expression level, for reference only.
In all cell lines, there is
62.6% cells with low copy number,
32.6% cells with medium copy number,
4.8% cells with high copy number
of DR1 gene.
Cell line is not selected, unable to assess the accurate copy number, for reference only.
Ubigene is an international high-technology enterprise focused on gene-editing cells. Our exclusive CRISPR-U™ technology has 10-20 times more efficient editing than traditional methods, easily achieving gene knockout, point mutation, and knock-in. Based on CRISPR-U™ technology, Ubigene has accumulated over 6000 successful gene-editing cases from more than 300 cell lines including iPSC and ESC, and has established a KO Cell Line Bank with 4500+ KO cell lines and Red Cotton™ gRNA Plasmid Bank with 10000+ gRNA plasmids available in stock.
Ubigene focuses on technological innovation and product development, of which EZ-editor™ series products that cover the whole workflow of gene-editing keep improving. Ubigene will move on toward our goal of "Make genome editing easier" and we won't stop!
EZ-editor™ Gene Dependency
EZ-editor™ Gene Expression Level 
EZ-editor™ Gene Copy Number 
